# An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)

> **NCT05146882** · PHASE2 · WITHDRAWN · sponsor: **Dicerna Pharmaceuticals, Inc., a Novo Nordisk company**

## Conditions studied

- Alpha 1-Antitrypsin Deficiency

## Interventions

- **DRUG:** Belcesiran

## Key facts

- **NCT ID:** NCT05146882
- **Lead sponsor:** Dicerna Pharmaceuticals, Inc., a Novo Nordisk company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12
- **Primary completion:** 2022-05-23
- **Final completion:** 2022-05-23
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Update to Program Design - No Participants Enrolled
- **Last updated:** 2024-09-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05146882

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05146882, "An Extension Study of Belcesiran in Patients With Alpha-1 Antitrypsin Deficiency Associated Liver Disease (AATLD)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05146882. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*